Published in Cancer Biother Radiopharm on August 01, 2008
(212)Pb-radioimmunotherapy induces G(2) cell-cycle arrest and delays DNA damage repair in tumor xenografts in a model for disseminated intraperitoneal disease. Mol Cancer Ther (2012) 1.06
Pretargeted radioimmunotherapy for hematologic and other malignancies. Cancer Biother Radiopharm (2010) 0.86
Tumor-Absorbed Dose Predicts Progression-Free Survival Following (131)I-Tositumomab Radioimmunotherapy. J Nucl Med (2014) 0.81
Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys (1991) 13.16
Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol (1995) 9.03
131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med (2005) 3.38
Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol (2006) 2.79
Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. J Nucl Med (2003) 2.76
Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol (2001) 2.71
Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol (2005) 2.55
Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol (2002) 2.41
A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood (2000) 2.11
Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results. J Clin Oncol (2005) 1.83
Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci U S A (2000) 1.81
64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. J Nucl Med (2001) 1.80
Receptor imaging in oncology by means of nuclear medicine: current status. J Clin Oncol (2004) 1.69
Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet (1995) 1.69
Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas. Blood (2002) 1.67
Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results. Cancer Biother Radiopharm (2000) 1.65
The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle. J Immunol (1985) 1.57
Pretargeted radioimmunotherapy of cancer: progress step by step. J Nucl Med (2003) 1.56
A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. Blood (2001) 1.52
Radiolabelling DOTA-peptides with 68Ga. Eur J Nucl Med Mol Imaging (2005) 1.51
Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer (2004) 1.51
Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc Natl Acad Sci U S A (2006) 1.50
Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods. Clin Cancer Res (2005) 1.49
High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood (2002) 1.45
Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med (2006) 1.44
Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. J Nucl Med (2005) 1.41
Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol (2005) 1.35
Multifunctional antibodies by the Dock-and-Lock method for improved cancer imaging and therapy by pretargeting. J Nucl Med (2007) 1.35
(111)In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer. J Nucl Med (2007) 1.25
Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma. Blood (2004) 1.24
Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood (2004) 1.24
The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res (2004) 1.22
Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood (2002) 1.20
Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol (1998) 1.13
Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med (2005) 1.13
Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J Clin Oncol (1998) 1.07
Rationales, evidence, and design considerations for fractionated radioimmunotherapy. Cancer (2002) 1.05
Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts. Proc Natl Acad Sci U S A (1997) 1.04
Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy. Blood (2007) 1.03
Tositumomab and (131)I therapy in non-Hodgkin's lymphoma. J Nucl Med (2005) 1.02
Pretreatment with rituximab enhances radiosensitivity of non-Hodgkin's lymphoma cells. J Radiat Res (2005) 0.99
Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody. Cancer Biother Radiopharm (1998) 0.96
Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy. J Natl Cancer Inst (1990) 0.96
Combination therapy with Pretarget CC49 radioimmunotherapy and gemcitabine prolongs tumor doubling time in a murine xenograft model of colon cancer more effectively than either monotherapy. Clin Cancer Res (2003) 0.95
Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin's lymphoma. Clin Lymphoma (2000) 0.95
Update: affibody molecules for molecular imaging and therapy for cancer. Cancer Biother Radiopharm (2007) 0.93
Targeted alpha-particle therapy of microscopic disease: Providing a further rationale for clinical investigation. J Nucl Med (2006) 0.92
Cancer Imaging and Therapy with Bispecific Antibody Pretargeting. Update Cancer Ther (2007) 0.90
Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's lymphoma. Cancer Biother Radiopharm (2005) 0.90
Three-step radioimmunotherapy with yttrium-90 biotin: dosimetry and pharmacokinetics in cancer patients. Eur J Nucl Med (1999) 0.89
Intraperitoneal radioimmunochemotherapy of ovarian cancer: a phase I study. Cancer Biother Radiopharm (2001) 0.89
Selective high-affinity ligand antibody mimics for cancer diagnosis and therapy: initial application to lymphoma/leukemia. Clin Cancer Res (2007) 0.88
In vitro evaluation of radioprotective and radiosensitizing effects of rituximab. J Nucl Med (2008) 0.85
Single-Dose versus fractionated radioimmunotherapy of human colon carcinoma xenografts using 131I-labeled multivalent CC49 single-chain fvs. Clin Cancer Res (2001) 0.85
Engineering multivalent antibody fragments for in vivo targeting. Methods Mol Biol (2004) 0.84
The epidermal growth factor receptor: a new target for anticancer therapy. Curr Probl Cancer (2002) 0.84
The biologic window for chimeric L6 radioimmunotherapy. Cancer (1994) 0.84
Direct antilymphoma effects on human lymphoma cells of monotherapy and combination therapy with CD20 and HLA-DR antibodies and 90Y-labeled HLA-DR antibodies. Clin Cancer Res (2005) 0.82
Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a phase I clinical trial. J Nucl Med (1997) 0.81
Nanomolecular HLA-DR10 antibody mimics: A potent system for molecular targeted therapy and imaging. Cancer Biother Radiopharm (2008) 0.81
Cure of incurable lymphoma. Int J Radiat Oncol Biol Phys (2006) 0.81
Radioisotopic localization of (90)Yttrium-ibritumomab tiuxetan in patients with CD20+ non-Hodgkin's lymphoma. Mol Imaging Biol (2008) 0.81
Importance of temporal relationships in combined modality radioimmunotherapy of breast carcinoma. Cancer (1997) 0.80
Molecular radiotherapy with somatostatin analogs for (neuro-)endocrine tumors. J Endocrinol Invest (2005) 0.80
Characteristics of dimeric (bis) bidentate selective high affinity ligands as HLA-DR10 beta antibody mimics targeting non-Hodgkin's lymphoma. Int J Oncol (2007) 0.79
Update: aptamers as novel radiopharmaceuticals: their applications and future prospects in diagnosis and therapy. Cancer Biother Radiopharm (2007) 0.79
High-dose 90Y Mx-diethylenetriaminepentaacetic acid (DTPA)-BrE-3 and autologous hematopoietic stem cell support (AHSCS) for the treatment of advanced breast cancer: a phase I trial. Cancer Res (1995) 0.79
Initial clinical experience evaluating Yttrium-90-chimeric T84.66 anticarcinoembryonic antigen antibody and autologous hematopoietic stem cell support in patients with carcinoembryonic antigen-producing metastatic breast cancer. Clin Cancer Res (1999) 0.79
Synthesis and radiolabeling of selective high-affinity ligands designed to target non-Hodgkin's lymphoma and leukemia. Bioconjug Chem (2007) 0.79
Concepts in radioimmunotherapy and immunotherapy: Radioimmunotherapy from a Lym-1 perspective. Semin Oncol (2005) 0.79
Direct antilymphoma activity of novel, first-generation "antibody mimics" that bind HLA-DR10-positive non-Hodgkin's lymphoma cells. Cancer Biother Radiopharm (2006) 0.78
Dosimetry-based therapy in metastatic breast cancer patients using 90Y monoclonal antibody 170H.82 with autologous stem cell support and cyclosporin A. Clin Cancer Res (1999) 0.78
Effect of recombinant alpha-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trial. Clin Cancer Res (1997) 0.76
Dose fractionation of radiolabeled antibodies in patients with metastatic colon cancer. J Nucl Med (1992) 0.76
Application of high amplitude alternating magnetic fields for heat induction of nanoparticles localized in cancer. Clin Cancer Res (2005) 2.13
Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res (2002) 1.59
Dynamic force spectroscopy of parallel individual Mucin1-antibody bonds. Proc Natl Acad Sci U S A (2005) 1.58
Mechanism of DNA compaction by yeast mitochondrial protein Abf2p. Biophys J (2004) 1.09
Crystal structure of Clostridium botulinum neurotoxin protease in a product-bound state: Evidence for noncanonical zinc protease activity. Proc Natl Acad Sci U S A (2004) 1.08
Rationales, evidence, and design considerations for fractionated radioimmunotherapy. Cancer (2002) 1.05
Construction of di-scFv through a trivalent alkyne-azide 1,3-dipolar cycloaddition. Chem Commun (Camb) (2006) 1.05
Computational approaches for identification of conserved/unique binding pockets in the A chain of ricin. Bioinformatics (2005) 1.05
Packaging of single DNA molecules by the yeast mitochondrial protein Abf2p. Biophys J (2003) 1.04
Production of soluble ScFvs with C-terminal-free thiol for site-specific conjugation or stable dimeric ScFvs on demand. Bioconjug Chem (2004) 1.03
Protamine 1: protamine 2 stoichiometry in the sperm of eutherian mammals. Mol Reprod Dev (2002) 1.02
Impact of nodal regression on radiation dose for lymphoma patients after radioimmunotherapy. J Nucl Med (2003) 0.97
Condensation of DNA by spermatid basic nuclear proteins. J Biol Chem (2002) 0.95
Survival benefit associated with human anti-mouse antibody (HAMA) in patients with B-cell malignancies. Cancer Immunol Immunother (2006) 0.94
Raman spectroscopy of DNA packaging in individual human sperm cells distinguishes normal from abnormal cells. J Biophotonics (2009) 0.93
Development of multivalent radioimmunonanoparticles for cancer imaging and therapy. Cancer Biother Radiopharm (2008) 0.93
Dynamics of protamine 1 binding to single DNA molecules. J Biol Chem (2003) 0.89
Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium-DOTA-peptide-ChL6. Prostate (2002) 0.89
Selective high-affinity ligand antibody mimics for cancer diagnosis and therapy: initial application to lymphoma/leukemia. Clin Cancer Res (2007) 0.88
Recombinant antibodies: from the laboratory to the clinic. Cancer Biother Radiopharm (2006) 0.88
The remarkable stability of chimeric, sialic acid-derived alpha/delta-peptides in human blood plasma. Chem Biol Drug Des (2010) 0.88
Combined modality radioimmunotherapy. Promise and peril. Cancer (2002) 0.88
Selection and characterization of anti-MUC-1 scFvs intended for targeted therapy. Clin Cancer Res (2003) 0.87
Monitoring dynamic protein expression in living E. coli. Bacterial cells by laser tweezers Raman spectroscopy. Cytometry A (2007) 0.87
Pharmacokinetic characterization in xenografted mice of a series of first-generation mimics for HLA-DR antibody, Lym-1, as carrier molecules to image and treat lymphoma. J Nucl Med (2007) 0.87
Characterization of site-specific ScFv PEGylation for tumor-targeting pharmaceuticals. Bioconjug Chem (2005) 0.85
Mass spectrometry and non-covalent protein-ligand complexes: confirmation of binding sites and changes in tertiary structure. J Am Soc Mass Spectrom (2003) 0.85
Characterization of human IgG antimouse antibody in patients with B-cell malignancies. Clin Cancer Res (2003) 0.85
Combining constitutive materials modeling with atomic force microscopy to understand the mechanical properties of living cells. Proc Natl Acad Sci U S A (2002) 0.84
A general chemical synthesis platform for crosslinking multivalent single chain variable fragments. Org Biomol Chem (2011) 0.82
Direct antilymphoma effects on human lymphoma cells of monotherapy and combination therapy with CD20 and HLA-DR antibodies and 90Y-labeled HLA-DR antibodies. Clin Cancer Res (2005) 0.82
Nanomolecular HLA-DR10 antibody mimics: A potent system for molecular targeted therapy and imaging. Cancer Biother Radiopharm (2008) 0.81
Cure of incurable lymphoma. Int J Radiat Oncol Biol Phys (2006) 0.81
Update: Turning the heat on cancer. Cancer Biother Radiopharm (2008) 0.80
Concepts, consequences, and implications of theranosis. Semin Nucl Med (2012) 0.80
Radiation dosimetry for radionuclide therapy in a nonmyeloablative strategy. Cancer Biother Radiopharm (2002) 0.79
Self-assembly of heptameric nanoparticles derived from tag-functionalized phi29 connectors. ACS Nano (2010) 0.79
Characteristics of dimeric (bis) bidentate selective high affinity ligands as HLA-DR10 beta antibody mimics targeting non-Hodgkin's lymphoma. Int J Oncol (2007) 0.79
Synthesis and radiolabeling of selective high-affinity ligands designed to target non-Hodgkin's lymphoma and leukemia. Bioconjug Chem (2007) 0.79
Use of atomic force microscopy for morphological and morphometric analyses of acrosome intact and acrosome-reacted human sperm. Mol Reprod Dev (2002) 0.79
Splenic volume change and nodal tumor response in non-Hodgkin's lymphoma patients after radioimmunotherapy using radiolabeled Lym-1 antibody. Cancer Biother Radiopharm (2005) 0.79
Application of NMR methods to identify detection reagents for use in development of robust nanosensors. Methods Mol Biol (2005) 0.78
Single molecule studies of DNA-protamine interactions. Protein Pept Lett (2011) 0.78
Planning time for peripheral blood stem cell infusion after high-dose targeted radionuclide therapy using dosimetry. J Nucl Med (2005) 0.78
Direct antilymphoma activity of novel, first-generation "antibody mimics" that bind HLA-DR10-positive non-Hodgkin's lymphoma cells. Cancer Biother Radiopharm (2006) 0.78
Identification of novel small molecules that bind to two different sites on the surface of tetanus toxin C fragment. Chem Res Toxicol (2002) 0.78
Preclinical evaluation of cathepsin-degradable peptide linkers for radioimmunoconjugates. Clin Cancer Res (2003) 0.78
Time-dependent measure of a nanoscale force-pulse driven by the axonemal dynein motors in individual live sperm cells. Nanomedicine (2010) 0.78
Recombinant expression of the beta-subunit of HLA-DR10 for the selection of novel lymphoma targeting molecules. Cancer Biother Radiopharm (2007) 0.77
Documentation of idiotypic cascade after Lym-1 radioimmunotherapy in a patient with non-Hodgkin's lymphoma: basis for extended survival? Clin Cancer Res (2003) 0.77
In-vivo biodistribution and safety of 99mTc-LLP2A-HYNIC in canine non-Hodgkin lymphoma. PLoS One (2012) 0.77
Electrospray mass spectrometry of NeuAc oligomers associated with the C fragment of the tetanus toxin. J Am Soc Mass Spectrom (2006) 0.76
Health care in the United States in 2009: both sides of the "counter". Cancer Biother Radiopharm (2009) 0.75
Identification of ligands that target the HCV-E2 binding site on CD81. J Comput Aided Mol Des (2013) 0.75
Implantation of different malignant human cell lines in an athymic mouse does not alter success and growth rates of either xenograft. Cancer Biother Radiopharm (2005) 0.75
Treatment planning for molecular targeted radionuclide therapy. Cancer Biother Radiopharm (2002) 0.75
Evaluation of a cathepsin-cleavable peptide linked radioimmunoconjugate of a panadenocarcinoma MAb, m170, in mice and patients. Cancer Biother Radiopharm (2004) 0.75
Identification of a thermo-regulated glutamine-binding protein from Yersinia pestis. Protein Pept Lett (2008) 0.75
Extracellular domain of myelin oligodendrocyte glycoprotein (MOG) exhibits solvent-dependent conformational transitions. Protein Pept Lett (2003) 0.75
Effect of antilymphoma antibody, 131I-Lym-1, on peripheral blood lymphocytes in patients with non-Hodgkin's lymphoma. Cancer Biother Radiopharm (2007) 0.75
Comparison of normal tissue pharmacokinetics with 111In/90Y monoclonal antibody m170 for breast and prostate cancer. Int J Radiat Oncol Biol Phys (2006) 0.75
Protamines. Editorial. Protein Pept Lett (2011) 0.75
Components of professional competence for nuclear medicine physicians. J Nucl Med (2003) 0.75
Selecting an intervention time for intravascular enzymatic cleavage of peptide linkers to clear radioisotope from normal tissues. Cancer Biother Radiopharm (2007) 0.75